120
Participants
Start Date
August 31, 2012
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Ibrutinib
Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
La Jolla
Los Angeles
Stanford
Norwalk
Jacksonville
Chicago
Peoria
Goshen
Iowa City
Sioux City
Westwood
Lexington
Louisville
Metairie
Baltimore
Boston
Worcester
Ann Arbor
Detroit
Jefferson City
St Louis
Omaha
Hackensack
New York
Syracuse
Watertown
Nashville
Houston
Burlington
Charlottesville
Morgantown
Madison
Bruges
Ghent
Grenoble
Mulhouse
Nantes
Pessac
Vandœuvre-lès-Nancy
Afula
Beer Yaakov
Hadera
Haifa
Nahariya
Petah Tikva
Ramat Gan
Chorzów
Lodz
San Juan
Nizhny Novgorod
Rostov-on-Don
Saint Petersburg
Barcelona
Salamanca
London
Plymouth
Collaborators (1)
Pharmacyclics LLC.
INDUSTRY
Janssen Research & Development, LLC
INDUSTRY